Searchable abstracts of presentations at key conferences on calcified tissues

ba0001pp140 | Cancer and bone: basic, translational and clinical | ECTS2013

NVP-BEZ235, a dual PI3K/mTOR inhibitor, inhibits osteosarcoma cell proliferation and the tumor development in vivo

Gobin Berengere , Battaglia Severine , Chesneau Julie , Heymann Dominique

Osteosarcoma is the most common primary malignant bone tumor, characterized by osteoid production and/or osteolytic lesions of bone. Despite recent improvements in chemotherapy and surgery, the problem of non-response to chemotherapy remains and constitutes a poor prognosis parameter. Consequently new therapeutic strategies aim to improve the overall rate of survival. The present work investigated the therapeutic interest of a dual phosphatidylinositol-3-kinase (PI3K)/mammalia...

ba0001pp139 | Cancer and bone: basic, translational and clinical | ECTS2013

New PI3Kα-specific inhibitor, BYL719: therapeutic interest in osteosarcoma

Gobin Berengere , Baud'huin Marc , Charrier Celine , Hervouet Soizic , Lezot Frederic , Blanchard Frederic , Heymann Dominique

It has been established that disturbances of intracellular signaling pathways strongly contribute to the oncologic process. Indeed, phosphatidylinositol-3-kinase (PI3K) became a key target in cancer therapy, due to its high frequency of mutation and/or gain of function of its catalytic subunits in cancer cells. In this context, we investigated the in vitro and in vivo effects of a new PI3Kα inhibitor, BYL719 (Novartis Pharma), on bone cells and its thera...

ba0001pp141 | Cancer and bone: basic, translational and clinical | ECTS2013

Therapeutic interest of Imatinib Mesylate in osteosarcoma

Gobin Berengere , Moriceau Gatien , Ory Benjamin , Brion Regis , Redini Francoise , Heymann Dominique

Osteosarcoma is the most common primary malignant bone tumor, characterized by osteoid production and/or osteolytic lesions of bone. A lack of response to chemotherapeutic treatments points out the importance of exploring new therapeutic ways. Imatinib Mesylate (Glivec, Novartis Pharma), a tyrosine kinase inhibitor, has been originally developed for the treatment of chronic myeloid leukemia. Several studies revealed that Imatinib Mesylate inhibits osteoclast differentiation th...

ba0001pp339 | Osteoporosis: evaluation and imaging | ECTS2013

What is the performance in vertebral fracture discrimination by bone mineral density, micro-architecture estimation, and FRAX in stand-alone, combined or adjusted approaches: the OsteoLaus Study

Lamy Olivier , Krieg Marc-Antoine , Stoll Delphine , Aubry-Rozier Berengere , Metzger Marie , Hans Didier

The aim of the study is to compare the performance of FRAX vs TBS adjusted FRAX using Leslie B et al.1 method to better identify women at high fracture risk. The OsteoLaus cohort (1500 women 50–80 years living in Lausanne, CH) started in 2010. CRF for OP, FRAX, spine and hip BMD, VFA by DXA and TBS were recorded. Sensitivity and specificity in regard to vertebral fracture grade 2 and 3 has been calculated. Net reclassification improvement (NRI) had als...

ba0001pp142 | Cancer and bone: basic, translational and clinical | ECTS2013

Over-expression of Smad7 in osteosarcoma cells inhibits primary tumor growth, the associated bone osteolysis and the development of lung metastasis in murine xenograft model

Lamora Audrey , Talbot Julie , Gobin Berengere , Leduc Marion , Taurelle Julien , Brion Regis , Heymann Dominique , Redini Francoise , Verrecchia Franck

Osteosarcoma, the main malignant primary bone tumor, affects a ‘young’ population composed of children and young adults. Current treatment consists of tumor resection associated with chemotherapy. Unfortunately in many cases, a lack of response to anti-tumor drugs is observed, leading to development of metastases and to the patient’s death. Because TGF-β promotes metastases from many solid epithelial tumors, we investigated the effect of inhibitory Smad7 ov...